3109 T3D3067 Vapreotide Vapreotide is only found in individuals that have used or taken this drug. It is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (A2442). 103222-11-3 23725064 C57H70N12O9S2 1130.483010 White powder. 3.99e-03 g/L The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (A2442). Route of Elimination: Vapreotide is 76% eliminated in bile. The remainder is renally eliminated. Half Life: 30 minutes No indication of carcinogenicity to humans (not listed by IARC). For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea. Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide. 2009-07-21T20:29:00Z 2016-11-09T01:08:46Z Vapreotide DB04894 true CC(C)C1NC(=O)C(CCCCN)NC(=O)C(CC2=CNC3=C2C=CC=C3)NC(=O)C(CC2=CC=C(O)C=C2)NC(=O)C(CSSCC(NC1=O)C(=O)NC(CC1=CC2=CC=CC=C2N1)C(N)=O)NC(=O)C(N)CC1=CC=CC=C1 C57H70N12O9S2 InChI=1S/C57H70N12O9S2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)28-37-26-35-14-6-8-16-41(35)62-37)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-38(70)22-20-34)53(74)66-46(27-36-29-61-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58/h3-9,12-17,19-22,26,29,32,40,43-49,61-62,70H,10-11,18,23-25,27-28,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73) GAWXLRUZZFSQON-UHFFFAOYSA-N 1131.371 1130.483013278 Exogenous Solid HMDB15601 CHEMBL2103975 64425 <p>Venkata Raghavendra Palle, Maheedhara Reddy Challa, &#8220;<span class="caps">PROCESS</span> <span class="caps">FOR</span> <span class="caps">PREPARING</span> <span class="caps">VAPREOTIDE</span>.&#8221; U.S. Patent US20070111930, issued May 17, 2007.</p> CHEM002409 350.64 306.20410000000004 118.81987412749159 18 11 13 9.427821371235487 10.261460337042891 2 7 2.70 -5.45 3.99e-03 g/l